Thrivent Financial for Lutherans’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $80.3M | Sell |
|
|||||
|
2025
Q2 | $99M | Sell |
|
|||||
|
2025
Q1 | $97.2M | Buy |
|
|||||
|
2024
Q4 | $101M | Buy |
|
|||||
|
2024
Q3 | $2.97M | Sell |
|
|||||
|
2024
Q2 | $6.41M | Buy |
|
|||||
|
2024
Q1 | $3.44M | Buy |
|
|||||
|
2023
Q4 | $3.23M | Buy |
|
|||||
|
2023
Q3 | $2.75M | Sell |
|
|||||
|
2023
Q2 | $2.38M | Sell |
|
|||||
|
2023
Q1 | $2.58M | Sell |
|
|||||
|
2022
Q4 | $3.62M | Buy |
|
|||||
|
2022
Q3 | $2.69M | Buy |
|
|||||
|
2022
Q2 | $2.44M | Buy |
|
|||||
|
2022
Q1 | $2.32M | Sell |
|
|||||
|
2021
Q4 | $2.13M | Buy |
|
|||||
|
2021
Q3 | $2.37M | Sell |
|
|||||
|
2021
Q2 | $2.44M | Buy |
|
|||||
|
2021
Q1 | $2.43M | Buy |
|
|||||
|
2020
Q4 | – | Sell |
|
|||||
|
2020
Q3 | $3.42M | Sell |
|
|||||
|
2020
Q2 | $27.8M | Buy |
|
|||||
|
2020
Q1 | $19.6M | Sell |
|
|||||
|
2019
Q4 | $24.4M | Buy |
|
|||||
|
2019
Q3 | $18.6M | Buy |
|
|||||
|
2019
Q2 | $16.9M | Buy |
|
|||||
|
2019
Q1 | $16.4M | Sell |
|
|||||
|
2018
Q4 | $49.4M | Buy |
|
|||||
|
2018
Q3 | $43.7M | Buy |
|
|||||
|
2018
Q2 | $25M | Buy |
|
|||||
|
2018
Q1 | $20.8M | Sell |
|
|||||
|
2017
Q4 | $19.5M | Sell |
|
|||||
|
2017
Q3 | $15.5M | Hold |
|
|||||
|
2017
Q2 | $11.6M | Hold |
|
|||||
|
2017
Q1 | $10.9M | Hold |
|
|||||
|
2016
Q4 | $9.78M | Sell |
|
|||||
|
2016
Q3 | $12.8M | Buy |
|
|||||
|
2016
Q2 | $11.3M | Hold |
|
|||||
|
2016
Q1 | $9.84M | Buy |
|
|||||
|
2015
Q4 | $13.9M | Sell |
|
|||||
|
2015
Q3 | $11.2M | Buy |
|
|||||
|
2015
Q2 | $10.9M | Buy |
|
|||||
|
2015
Q1 | $8.91M | Sell |
|
|||||
|
2014
Q4 | $14.4M | Sell |
|
|||||
|
2014
Q3 | $10.3M | Sell |
|
|||||
|
2014
Q2 | $9.96M | Sell |
|
|||||
|
2014
Q1 | $10.8M | Buy |
|
|||||
|
2013
Q4 | $4.19M | Buy |
|
|||||
|
2013
Q3 | $3.85M | Sell |
|
|||||
|
2013
Q2 | $4.64K | Buy |
|